US Drugmakers Pool Talent Plans as $2 Billion Biopharma Expansions Strain Workforce
Updated
Updated · Pharmaceutical Technology · Jun 23
US Drugmakers Pool Talent Plans as $2 Billion Biopharma Expansions Strain Workforce
3 articles · Updated · Pharmaceutical Technology · Jun 23
Summary
BIO 2026 speakers said US drugmakers are increasingly sharing hiring plans and training efforts through trade associations instead of competing for the same local workers.
Billions of dollars in new US manufacturing and R&D commitments—made as companies onshore operations and seek relief from Trump pharmaceutical tariffs—have sharply raised demand for skilled biopharma labor.
North Carolina has become a leading test case: J&J and Roche each committed $2 billion in 2025 and 2026, while Eli Lilly joined the state's Biotech Manufacturers Forum to coordinate talent-pipeline development with rivals.
That model grew from North Carolina's long-running effort to avoid poaching and now includes colleges and local government; smaller hubs such as Oregon are adopting similar forums to share workforce needs.